182 related articles for article (PubMed ID: 34526571)
21. The diagnostic or prognostic values of FADD in cancers based on pan‑cancer analysis.
Wang C; Jiang X; Zhao Q; Xie Z; Cai H
Biomed Rep; 2023 Nov; 19(5):77. PubMed ID: 37829257
[TBL] [Abstract][Full Text] [Related]
22. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking.
Arcila ME; Drilon A; Sylvester BE; Lovly CM; Borsu L; Reva B; Kris MG; Solit DB; Ladanyi M
Clin Cancer Res; 2015 Apr; 21(8):1935-43. PubMed ID: 25351745
[TBL] [Abstract][Full Text] [Related]
23. Significance of Chr9p22.1-p21.3 Deletion in Cancer Development: A Pan-cancer
Gonçalves PG; Reis RM; Bidinotto LT
Anticancer Res; 2022 Nov; 42(11):5291-5304. PubMed ID: 36288884
[TBL] [Abstract][Full Text] [Related]
24. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
25. CASC5 is a potential tumour driving gene in lung adenocarcinoma.
Cui Y; Zhang C; Ma S; Guo W; Cao W; Guan F
Cell Biochem Funct; 2020 Aug; 38(6):733-742. PubMed ID: 32283571
[TBL] [Abstract][Full Text] [Related]
26. Pan-Cancer Transcriptome and Immune Infiltration Analyses Reveal the Oncogenic Role of Far Upstream Element-Binding Protein 1 (FUBP1).
Wang H; Zhang R; Li E; Yan R; Ma B; Ma Q
Front Mol Biosci; 2022; 9():794715. PubMed ID: 35274005
[TBL] [Abstract][Full Text] [Related]
27. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
28. Insights of fibroblast growth factor receptor 3 aberrations in pan-cancer and their roles in potential clinical treatment.
Li J; Hu K; Huang J; Zhou L; Yan Y; Xu Z
Aging (Albany NY); 2021 Jun; 13(12):16541-16566. PubMed ID: 34160364
[TBL] [Abstract][Full Text] [Related]
29. Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
Nicoś M; Krawczyk P; Jarosz B; Sawicki M; Michnar M; Trojanowski T; Milanowski J
Clin Transl Oncol; 2016 Oct; 18(10):1039-43. PubMed ID: 26860843
[TBL] [Abstract][Full Text] [Related]
30. RASSF7 promotes cell proliferation through activating MEK1/2-ERK1/2 signaling pathway in hepatocellular carcinoma.
Zhang M; Li Q; Zhang L; Wang Y; Wang L; Li Q; He T; Wan B; Wang X
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):73-79. PubMed ID: 29729697
[TBL] [Abstract][Full Text] [Related]
31. A Pan-Cancer Analysis of the Role of PBRM1 in Human Tumors.
Liu J; Xie X; Xue M; Wang J; Chen Q; Zhao Z; Sheng X
Stem Cells Int; 2022; 2022():7676541. PubMed ID: 36277039
[TBL] [Abstract][Full Text] [Related]
32. MEK1 and AKT2 mutations in Japanese lung cancer.
Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
J Thorac Oncol; 2010 May; 5(5):597-600. PubMed ID: 20354455
[TBL] [Abstract][Full Text] [Related]
33. Constitutive activation of mitogen-activated protein kinase kinase (MEK1) in ileal enterocytes leads to dysplasia and a predisposition to cancer.
Shneider BL; Cortes-Santiago N; Schady DA; Krishnamoorthy S; Thevananther S; Rajapakshe K; Perera D; Huang S; Coarfa C
Am J Physiol Gastrointest Liver Physiol; 2021 Mar; 320(3):G366-G379. PubMed ID: 33470189
[TBL] [Abstract][Full Text] [Related]
34. Pan-cancer analysis identifies ESM1 as a novel oncogene for esophageal cancer.
Cui Y; Guo W; Li Y; Shi J; Ma S; Guan F
Esophagus; 2021 Apr; 18(2):326-338. PubMed ID: 33175267
[TBL] [Abstract][Full Text] [Related]
35. Graded activation of the MEK1/MT1-MMP axis determines renal epithelial cell tumor phenotype.
Mahimkar R; Alfonso-Jaume MA; Cape LM; Dahiya R; Lovett DH
Carcinogenesis; 2011 Dec; 32(12):1806-14. PubMed ID: 21965271
[TBL] [Abstract][Full Text] [Related]
36. How activating mutations affect MEK1 regulation and function.
Jindal GA; Goyal Y; Humphreys JM; Yeung E; Tian K; Patterson VL; He H; Burdine RD; Goldsmith EJ; Shvartsman SY
J Biol Chem; 2017 Nov; 292(46):18814-18820. PubMed ID: 29018093
[TBL] [Abstract][Full Text] [Related]
37. Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy.
Gannon HS; Kaplan N; Tsherniak A; Vazquez F; Weir BA; Hahn WC; Meyerson M
Mol Cancer Res; 2016 Feb; 14(2):207-15. PubMed ID: 26582713
[TBL] [Abstract][Full Text] [Related]
38. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.
Estep AL; Palmer C; McCormick F; Rauen KA
PLoS One; 2007 Dec; 2(12):e1279. PubMed ID: 18060073
[TBL] [Abstract][Full Text] [Related]
39. Bioinformatics and survival analysis of glia maturation factor-γ in pan-cancers.
Lan A; Ren C; Wang X; Tong G; Yang G
BMC Cancer; 2021 Apr; 21(1):423. PubMed ID: 33863293
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of
Fei L; Lu Z; Xu Y; Hou G
Front Genet; 2022; 13():920897. PubMed ID: 36035140
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
